Dr. Lindsay Ogle, an MD who covers metabolic health, talks through options for people whose appetite hasn't settled on GLP-1 treatment.
Recap by typeshit. Full story at Metabolic Health with Dr. Lindsay Ogle, MD.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
The Form 483 cites microbial growth in a clean hood, reversed cleanroom air pressure and active ingredients marked for research use only. Check which pharmacy filled your vial.
Loading…